Exagen Inc.

Equities

XGN

US30068X1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.412 ^USD	+0.15%		+3.07%	-29.04%

Apr. 26	Exagen Inc. Announces Changes in Board of Directors	CI
Mar. 18	Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

March 18, 2024 at 08:00 am EDT

Exagen Inc. provided earnings guidance for the first quarter and full year 2024. For first quarter 2024 revenue, the company is providing a guidance range of $13.0 million to $13.5 million.

For full-year 2024 revenue, the company is providing guidance of approximately $54 million.

Latest news about Exagen Inc.

Exagen Inc. Announces Changes in Board of Directors	Apr. 26	CI
Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $13.8M, vs. Street Est of $11.6M	Mar. 18	MT
Transcript : Exagen Inc., Q4 2023 Earnings Call, Mar 18, 2024	Mar. 18
Exagen Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 18	CI
Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023	Jan. 07	CI
Exagen Files $150 Million Mixed Shelf	Nov. 20	MT
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Transcript : Exagen Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $13.4M, vs. Street Est of $10.3M	Nov. 13	MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use	23-10-18	MT
Exagen Reaches Settlement With US Department of Justice Over Alleged Kickbacks to Promote Lab Test Use	23-10-17	MT
Exagen Agrees to Pay Over $650K to Resolve Kickback Allegations	23-10-17	DJ
Transcript : Exagen Inc., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07
Earnings Flash (XGN) EXAGEN Reports Q2 Revenue $14.1M, vs. Street Est of $10.9M	23-08-07	MT
Exagen Inc. Provides Revenue Guidance for the Third Quarter of 2023	23-08-07	CI
Exagen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
North American Morning Briefing : Investors Await -2-	23-08-07	DJ
Exagen Inc. Appoints Paul Kim as Class II Director	23-07-24	CI
Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Transcript : Exagen Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
Earnings Flash (XGN) EXAGEN Posts Q1 Revenue $11.2M, vs. Street Est of $9.4M	23-05-15	MT
Exagen Inc. Provides Revenue Guidance for the Second Quarter of 2023	23-05-15	CI

Chart Exagen Inc.

Duration

Period

More charts

Company Profile

Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.

Sector

Healthcare Facilities & Services

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Exagen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.412 USD

Average target price

5.5 USD

Spread / Average Target

+289.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
EXAGEN INC.	-29.04%	24.34M
CVS HEALTH CORPORATION	-14.92%	84.68B
HCA HEALTHCARE, INC.	+13.30%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B
PURE HEALTH HOLDING	-31.75%	11.77B
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B
DAVITA INC.	+27.44%	11.71B

Other Healthcare Facilities & Services